Pipeline Expansion Novartis is actively enhancing its pipeline through strategic acquisitions and collaborations, including recent deals in immunology and oncology, indicating ongoing opportunities to introduce complementary therapeutics and expand offerings within its portfolio.
Focus on Oncology With significant investments in cancer treatments, including a $3 billion oncology deal and targeted therapies in breast cancer, there is a growing demand for innovative oncology solutions that can address mutation-driven markets and long-term pipeline growth.
Growth Strategy Despite patent expirations, Novartis projects consistent revenue growth driven by de-risked assets and late-stage pipeline development, presenting opportunities to provide support and solutions aligned with their strategic growth initiatives.
Market Confidence Novartis maintains a resilient sales trajectory with an 8% increase in 2025, supported by robust product performance and strategic acquisitions, signaling a stable platform for introducing new products or services that can further boost sales.
Therapeutic Innovation Focused on immunology and complex skin diseases, Novartis showcases a commitment to advancing medical data and new treatments, creating opportunities for collaborations, research support, and solutions tailored to their innovation-driven approach.
$10B
$10B
$10B
$10B
$10B
$10B
$10B
$10B
$10B
$10B
$10BNovartis uses 8 technology products and services including Adobe Analytics, Adobe Animate, FactSet, and more. Explore Novartis's tech stack below.
| Novartis Email Formats | Percentage |
| First.Last@novartis.com | 89% |
| F.Last@novartis.com | 5% |
| FiLast@novartis.com | 3% |
| FLast@novartis.com | 3% |
| First.Last@group.novartis.com | 98% |
| Last@group.novartis.com | 1% |
| Last.First@group.novartis.com | 1% |
| First.Last@pharma.novartis.com | 90% |
| Last.First@pharma.novartis.com | 1% |
| First.MiddleLast@pharma.novartis.com | 1% |
| F_Last@pharma.novartis.com | 1% |
| LastFirst@pharma.novartis.com | 1% |
| FLast@pharma.novartis.com | 1% |
| FirLast@pharma.novartis.com | 1% |
| First.Middle@pharma.novartis.com | 1% |
| Last_First@pharma.novartis.com | 1% |
| First_Last@pharma.novartis.com | 1% |
| FirstMiddle.Last@pharma.novartis.com | 1% |
Pharmaceutical ManufacturingBasel-stadt, Switzerland10001+ Employees
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
Company Overview
Media & News
Funding & FinancialsNovartis has raised a total of $2.5B of funding over 2 rounds. Their latest funding round was raised on Jun 19, 2024 in the amount of $2.5B.
Novartis's revenue is estimated to be in the range of $10B
Funding & FinancialsNovartis has raised a total of $2.5B of funding over 2 rounds. Their latest funding round was raised on Jun 19, 2024 in the amount of $2.5B.
Novartis's revenue is estimated to be in the range of $10B
1-888-653-2347 
support@leadiq.com